EFFICACY OF VONOPRAZAN VERSUS ESOMEPRAZOLE IN TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Articles in Press, Accepted Manuscript, Available Online from 02 August 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2025.397206.2613 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohammed Alsaeed Abdelbaky Rady   1; Dina Fathallah Mohamed 2; Mohammed Omar Abd El-Malek 3; Ahmed Shawky Ghanem 4
| ||||
| 1Department of Clinical Pharmacy, Police Hospital, Assiut, Egypt. | ||||
| 2Vice Dean of graduate studies and research, Faculty of Pharmacy , Assiut University. Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt. | ||||
| 3Department of Tropical medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt. | ||||
| 4Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt. | ||||
| Abstract | ||||
| Gastroesophageal reflux disease is among the most prevalent gastrointestinal disorders, with proton pump inhibitors forming the basis of current treatment. Recently, vonoprazan, a novel potassium-competitive acid blocker, has emerged as a promising alternative for acid suppression. This study aimed to compare the efficacy of vonoprazan 20 mg versus esomeprazole 40 mg, administered once daily, in relieving gastroesophageal reflux disease symptoms. In this prospective observational study, 200 patients diagnosed with gastroesophageal reflux disease were randomly assigned to two equal groups. Group A received esomeprazole 40 mg, while Group B received vonoprazan 20 mg daily for eight weeks. Symptom improvement was assessed using the Frequency Scale for the Symptoms of gastroesophageal reflux disease questionnaire. The study included 104 males and 96 females, with a mean age of 41.19 ± 12.9 years and a mean body mass index of 26.12 ± 3.71. Vonoprazan showed a greater reduction in reflux scores (14.9 ± 2.52 vs. 13.17 ± 0.03), dysmotility scores (10.87 ± 1.73 vs. 9.99 ± 1.26), and total scores (25.76 ± 4.07 vs. 23.16 ± 1.36) compared to esomeprazole. The symptom improvement rate was higher in the vonoprazan group (73.4%) than in the esomeprazole group (67.7%). No clinically significant adverse effects were reported in either group. Vonoprazan demonstrated superior efficacy to esomeprazole in alleviating gastroesophageal reflux disease symptoms, suggesting its potential as a more effective treatment option for acid-related disorders. | ||||
| Keywords | ||||
| Gastroesophageal reflux disease; Vonoprazan; Esomeprazole; Potassium-competitive acid blocker; Frequency scale of the symptoms of gastroesophageal reflux disease questionnaire | ||||
|
Statistics Article View: 77 |
||||
